GLUE
Monte Rosa Therapeutics, Inc.
Biotechnology · Healthcare · United States
10.76
close · 2026-10-30
value
61
cheaper than peers61
quality
33
stronger fundamentals33
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | 4.1% | 91 |
| price to book | 1.88× | 71 |
| cash flow yield, latest year | -3.0% | 70 |
| earnings yield, latest year | -5.5% | 61 |
| earnings yield, 1 year ago | -11.0% | 57 |
| cash flow yield, 2 years ago | -6.8% | 53 |
| earnings yield, 3 years ago | -21.4% | 42 |
| earnings yield, 2 years ago | -24.4% | 41 |
| cash flow yield, 3 years ago | -11.5% | 41 |
| price to sales | 31.96× | 28 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 7.8% | 66 |
| return on equity | -42.7% | 55 |
| operating margin | -547.8% | 32 |
| revenue growth | -61.3% | 15 |
4 of 4 measures available
Facts
| market cap | $918M |
| free cash flow | -$76.3M |
| employees | 150 |
| first trade | 2021-06-24 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.59 | -1.18 | -2.63 | -2.30 |
| free cash flow | -$27.5M | $38.0M | -$62.8M | -$105.4M |
| net income | -$38.6M | -$72.7M | -$135.4M | -$108.5M |
| revenue | $123.7M | $75.6M | $0 | $0 |
| unusual items | $1.5M | $416,000 | -$1.0M | $119,000 |